In a report published Thursday, Morgan Stanley analyst Bin Li reiterated an Overweight rating on WuXi PharmaTech WX, but removed the $45.00 price target.
In the report, Morgan Stanley noted, “1Q14 non-GAAP EPS of US$0.40 (+13% YoY) beat our estimate by 7% excluding FX impact and other gains (-$0.10 EPS impact). Although the increasing investment in new facilities, R&D and sales force expansion will continue to pressure OPM in 2014, all provide long term sustainable growth, in our view. Sales growth is unchanged at 14-16%YoY to US$660-$670mn. Excl. mark-to- market FX gain of US$0.20, non-GAAP EPS growth guidance increased to 10-13% YoY to US$2.00-$2.05 in 2014 (up from US$1.95-$2.00 previously) on the gain on venture investment. 2Q14 sales is forecasted to reach US$160-$162mn (+13-14% YoY) and Non-GAAP EPS to reach US$0.46-$0.48 (flat-3% YoY), including -US$0.01 FX loss (management's estimate).”
WuXi PharmaTech closed on Wednesday at $36.40.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in